]

GHIT Hit-to-Lead Program

Background

TB Alliance and Takeda Pharmaceutical Company Limited have an agreement to explore hits generated from a high-throughput screening program conducted to find novel compounds to improve treatment of tuberculosis. The joint research program is funded through the Global Health Innovative Technology (GHIT) Fund, established for the purpose of promoting research and development of pharmaceutical products, vaccines, and diagnostics needed for communicable diseases.

Collaboration began in June 2013, when TB Alliance and Takeda initiated a program to screen Takeda’s library of 20,000 proprietary compounds to identify potential candidates that showed promise to be further developed into new TB treatments.

Lead Identification
Partners
  • Takeda Pharmaceuticals